DE60310564D1 - Injizierbare depotformulierung enthaltend iloperidonkrystalle - Google Patents

Injizierbare depotformulierung enthaltend iloperidonkrystalle

Info

Publication number
DE60310564D1
DE60310564D1 DE60310564T DE60310564T DE60310564D1 DE 60310564 D1 DE60310564 D1 DE 60310564D1 DE 60310564 T DE60310564 T DE 60310564T DE 60310564 T DE60310564 T DE 60310564T DE 60310564 D1 DE60310564 D1 DE 60310564D1
Authority
DE
Germany
Prior art keywords
crystals
injectable depot
depot formulation
formulation containing
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60310564T
Other languages
English (en)
Other versions
DE60310564T2 (de
Inventor
Dierk Wieckhusen
Alexandra Glausch
Markus Ahlheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60310564(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60310564D1 publication Critical patent/DE60310564D1/de
Application granted granted Critical
Publication of DE60310564T2 publication Critical patent/DE60310564T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60310564T 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle Expired - Lifetime DE60310564T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0216416 2002-07-15
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds
PCT/EP2003/007619 WO2004006886A2 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone

Publications (2)

Publication Number Publication Date
DE60310564D1 true DE60310564D1 (de) 2007-02-01
DE60310564T2 DE60310564T2 (de) 2007-10-04

Family

ID=9940486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310564T Expired - Lifetime DE60310564T2 (de) 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle

Country Status (16)

Country Link
US (5) US20050250813A1 (de)
EP (1) EP1523335B1 (de)
JP (2) JP5392961B2 (de)
AT (1) ATE348635T1 (de)
AU (1) AU2003281154B2 (de)
CA (1) CA2492467C (de)
CY (1) CY1106305T1 (de)
DE (1) DE60310564T2 (de)
DK (1) DK1523335T3 (de)
ES (1) ES2279153T3 (de)
GB (1) GB0216416D0 (de)
HK (1) HK1076029A1 (de)
NZ (1) NZ537598A (de)
PT (1) PT1523335E (de)
WO (1) WO2004006886A2 (de)
ZA (1) ZA200410323B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578664A (zh) 2001-10-30 2005-02-09 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
EP2479290B1 (de) 2004-09-30 2020-08-19 Vanda Pharmaceuticals Inc. Verfahren zur Verabreichung von Iloperidon
EP2029136A4 (de) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc Behandlung für depressionserkrankungen
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
EP2170279B1 (de) 2007-07-31 2017-12-27 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung einer aripiprazol-suspension und einer gefriergetrockneten formulierung
WO2009036100A2 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
PT2222300E (pt) 2007-12-13 2014-07-28 Vanda Pharmaceuticals Inc Método e composição para tratamento de uma condição mediada por recetores da serotonina
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
EP2453891A1 (de) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Verwendung eines melatoninagonisten zur behandlung von schlafstörungen, u.a. primärer insomnie
US8802855B2 (en) 2009-09-19 2014-08-12 Zhejiang Huahai Pharmaceutical Co., Ltd. Method for preparation of iloperidone and crystallization method thereof
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
US20130004545A1 (en) * 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
EP2569325A4 (de) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp Verfahren zur reduzierung des innenaugendrucks beim menschen mithilfe von n6-cyclopentyladenosin (cpa), cpa-derivaten oder prodrugs davon
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
KR101936968B1 (ko) * 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
JP2015508751A (ja) 2012-01-26 2015-03-23 イノテック ファーマシューティカルズ コーポレイション ［（２ｒ，３ｓ，４ｒ，５ｒ）−５−（６−（シクロペンチルアミノ）−９ｈ−プリン−９−イル）−３，４−ジヒドロキシテトラヒドロフラン−２−イル］メチルナイトレートの無水多形体及びその製造方法
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
RU2632889C2 (ru) 2012-05-18 2017-10-11 Ванда Фармасьютиклз Инк. Метаболиты (1r-транс)-n-[[2-(2,3-дигидро-4-бензофуранил)циклопропил]-метил]пропанамида
RU2748386C2 (ru) 2012-12-18 2021-05-25 Ванда Фармасьютиклз Инк. Лечение расстройств циркадного ритма
MX2015013234A (es) * 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
EP3258935B1 (de) 2015-02-17 2021-04-07 Vanda Pharmaceuticals Inc. Loperidon zur behandlung von schizophrenie
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
WO2020117901A1 (en) * 2018-12-04 2020-06-11 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
JPS53108940A (en) * 1976-10-28 1978-09-22 Hoechst France Optically active nncarbethoxyyalphaa aminophenyl acetic acids * its preparation and its use for preparation of optically active alpha aminoophenylacetic acid
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) * 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DE69021645T2 (de) * 1989-05-19 1996-02-22 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
DE69125035T2 (de) * 1990-06-04 1997-07-10 Schering Corp Verfahren zur herstellung von interferon-alpha-2 kristallen
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
PT729357E (pt) 1993-11-19 2005-06-30 Janssen Pharmaceutica Nv 1,2-bwenzazoles microencapsulados
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
PL337027A1 (en) * 1997-05-26 2000-07-31 Akzo Nobel Nv Salts of aromatic sulphonic acids
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
HUP0103781A3 (en) 1998-10-16 2003-09-29 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
WO2001092334A1 (en) 2000-06-02 2001-12-06 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DK2305656T3 (da) * 2001-08-31 2013-02-11 Novartis Ag Optiske isomerer of en iloperidonmetabolit
CN1578664A (zh) * 2001-10-30 2005-02-09 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2003281154A1 (en) 2004-02-02
NZ537598A (en) 2006-07-28
AU2003281154B2 (en) 2006-10-12
EP1523335B1 (de) 2006-12-20
DK1523335T3 (da) 2007-01-29
US8227488B2 (en) 2012-07-24
US20090099232A1 (en) 2009-04-16
JP2011016849A (ja) 2011-01-27
CA2492467C (en) 2010-03-16
CA2492467A1 (en) 2004-01-22
JP5392961B2 (ja) 2014-01-22
ES2279153T3 (es) 2007-08-16
US8293765B2 (en) 2012-10-23
EP1523335A2 (de) 2005-04-20
JP5670698B2 (ja) 2015-02-18
PT1523335E (pt) 2007-02-28
ZA200410323B (en) 2006-06-28
ATE348635T1 (de) 2007-01-15
GB0216416D0 (en) 2002-08-21
US20050250813A1 (en) 2005-11-10
US20130012542A1 (en) 2013-01-10
DE60310564T2 (de) 2007-10-04
US8614232B2 (en) 2013-12-24
US20120156264A1 (en) 2012-06-21
WO2004006886A2 (en) 2004-01-22
JP2005533093A (ja) 2005-11-04
US20110212141A1 (en) 2011-09-01
WO2004006886A3 (en) 2004-02-19
CY1106305T1 (el) 2011-10-12
HK1076029A1 (en) 2006-01-06

Similar Documents

Publication Publication Date Title
DK1523335T3 (da) Injicerbar depotformulering omfattende iloperidonkrystaller
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CO6311078A2 (es) Compuestos heterociclicos que contienen dos o más heteroanillos, que contienen átomos de nitrogeno como únicos heteroátomos en el anillo, en donde al menos un anillo es de 6 miembros con un átomo de nitrógeno, que contienen tres ó más heteroátomos, c
WO2006020403A3 (en) 3-halo-2-oxopropionate salts and esters as novel anticancer agents
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
TW200626558A (en) Indazolone derivatives
AR073689A1 (es) Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.
BRPI0600194A (pt) composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
SE0202463D0 (sv) Novel compounds
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES
MX2007010881A (es) Composiciones de peroxido de benzoilo y metodos de uso.
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
PA8509801A1 (es) Compuestos antibioticos de azalida
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
TNSN08022A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
DE502005008631D1 (de) Dermatologischen zubereitungen
DE602005010886D1 (de) Zusammensetzungen mit trialkanolamin-alkoxylat-puffer
CO5231142A1 (es) TIADIAZOLA COMO INGREDIENTE ACTIVO, EN COMBINACIàN CON AL ME NOS UN FUNGICIDA SELECCIONADO DE LOS COMPONENTES QUE TIENE UNA ACTIVIDAD FUNGICIDA CONTRA LAS ENFERMEDADES DE LAS PLAN- TAS Y UN METODO PARA EL USO DEL MISMO
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
AR010321A1 (es) Granulos utiles para aplicaciones de oxidacion cuando se disuelven en presencia de una fuente activa de oxigeno, y composicion blanqueadora quecomprende a dichos granulos
ATE441420T1 (de) Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
AR062737A1 (es) Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento

Legal Events

Date Code Title Description
8363 Opposition against the patent